首页> 外文期刊>临床与转化肝病杂志(英文版) >A 3D Human Liver Model of Nonalcoholic Steatohepatitis
【24h】

A 3D Human Liver Model of Nonalcoholic Steatohepatitis

机译:非酒精脂肪性肝炎的3D人肝模型

获取原文
获取原文并翻译 | 示例
           

摘要

Background and Aims: To better understand nonalcoholic steatohepatitis (NASH) disease progression and to evaluate drug targets and compound activity, we undertook the devel-opment of an in vitro 3D model to mimic liver architecture and the NASH environment. Methods:We have developed an in vitro preclinical 3D NASH model by coculturing primary hu-man hepatocytes, human stellate cells, liver endothelial cells and Kupffer cells embedded in a hydrogel of rat collagen on a 96-well plate. A NASH-like environment was induced by ad-dition of medium containing free fatty acids and tumor ne-crosis factor-α. This model was then characterized by biochemical, imaging and transcriptomics analyses. Results:We succeeded in defining suitable culture conditions to main-tain the 3D coculture for up to 10 days in vitro, with the lowest level of steatosis and reproducible low level of inflammation and fibrosis. NASH disease was induced with a custom me-dium mimicking NASH features. The cell model exhibited the key NASH disease phenotypes of hepatocyte injury, steatosis, inflammation, and fibrosis. Hepatocyte injury was highlighted by a decrease of CYP3A4 expression and activity, without loss of viability up to day 10. Moreover, the model was able to stimulate a stable inflammatory and early fibrotic environ-ment, with expression and secretion of several cytokines. A global gene expression analysis confirmed the NASH induc-tion. Conclusions:This is a new in vitro model of NASH dis-ease consisting of four human primary cell-types that exhibits most features of the disease. The 10-day cell viability and cost effectiveness of the model make it suitable for medium throughput drug screening and provide attractive avenues to better understand disease physiology and to identify and characterize new drug targets.

著录项

  • 来源
    《临床与转化肝病杂志(英文版)》 |2020年第4期|P.359-370|共12页
  • 作者单位

    Translational Sciences Sanofi 1 Avenue Pierre Brossolette Chilly-Mazarin France;

    Translational Sciences Sanofi 1 Avenue Pierre Brossolette Chilly-Mazarin France;

    Translational Sciences Sanofi 1 Avenue Pierre Brossolette Chilly-Mazarin France;

    Translational Sciences Sanofi 1 Avenue Pierre Brossolette Chilly-Mazarin France;

    Translational Sciences Sanofi 1 Avenue Pierre Brossolette Chilly-Mazarin France;

    Translational Sciences Sanofi 1 Avenue Pierre Brossolette Chilly-Mazarin France;

    Translational Sciences Sanofi 1 Avenue Pierre Brossolette Chilly-Mazarin France;

    Translational Sciences Sanofi 1 Avenue Pierre Brossolette Chilly-Mazarin France;

    Translational Sciences Sanofi 1 Avenue Pierre Brossolette Chilly-Mazarin France;

    IT&M STATS Groupe IT&M Neuilly-sur-Seine France;

    Non Clinical Biostatistics Sanofi Vitry sur Seine France;

    Translational Sciences Sanofi 1 Avenue Pierre Brossolette Chilly-Mazarin France;

    Translational Sciences Sanofi 1 Avenue Pierre Brossolette Chilly-Mazarin France;

    Diabetes and Cardiovascular Research Sanofi Industriepark Höchst Frankfurt GermanyInstitute of Experimental Pharmacology Medical Faculty Mannheim University of Heidelberg Mannheim Germany;

    Translational Sciences Sanofi 1 Avenue Pierre Brossolette Chilly-Mazarin France;

    Translational Sciences Sanofi 1 Avenue Pierre Brossolette Chilly-Mazarin France;

    Translational Sciences Sanofi 1 Avenue Pierre Brossolette Chilly-Mazarin France;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 chi
  • 中图分类 消化系及腹部疾病;
  • 关键词

    3D liver model; Human primary cells; Key features of NASH;

获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号